Teva hits over two-month high as branded drugs boost quarterly profit

Teva Pharmaceutical Industries..

29/04/2026 16:54

** U.S.-listed shares of Israel-based drugmaker Teva Pharmaceutical TEVA.TA, TEVA.N rise 11.4% to $35.22, its highest in more than two months

** Co reports Q1 adj. profit of 53 cents per share vs analysts' average estimate of 48 cents per share - LSEG-compiled data

** Posts Q1 revenue of $3.98 billion, beating analysts' average expectation of $3.8 billion

** Co says earnings helped by branded drugs Austedo, Ajovy and Uzedy

** Adds quarterly sales of Huntington's disease drug Austedo rose 41% year-on-year to $578 million, offsetting pressure in generics

** Brokerage J.P. Morgan says investor focus is shifting to Teva's branded portfolio, with Austedo "growing nicely" and pipeline updates due later this year

** Including session's move, stock up 13% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))